Condition: Schizophrenia · Sponsor: LB Pharmaceuticals Inc.
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
This description comes directly from the study's public registry record.
Branislav Mancevski, MD · 212-605-0300 · clinicaltrials@lbpharma.us
Always discuss trial participation with your own doctor first.
| Chandler Clinical Trials | Chandler, Arizona, United States | Recruiting |
| Pillar Clinical Research | Bentonville, Arkansas, United States | Recruiting |
| Pillar Clinical Research | Little Rock, Arkansas, United States | Recruiting |
| Woodland International Research Group | Little Rock, Arkansas, United States | Recruiting |
| Advanced Research Center | Anaheim, California, United States | Recruiting |
| Synapse Clinical Trials | Cerritos, California, United States | Recruiting |
| ProScience Research Group | Culver City, California, United States | Recruiting |
| CenExel | Culver City, California, United States | Recruiting |
| Synergy San Diego | San Diego, California, United States | Recruiting |
| CenExel | Hollywood, Florida, United States | Recruiting |
| Segal Trials | Miami Lakes, Florida, United States | Recruiting |
| Health Synergy Clinical Research | West Palm Beach, Florida, United States | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07369154